Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Clinical significance of serum growth-regulated oncogene α (GROα) in patients with gynecological cancer
1 Department of Obstetrics and Gynecology, Nagoya City University, Graduate School of Medicine
2 Clinical Research Management Center, Nagoya City University, Nagoya (Japan)
Eur. J. Gynaecol. Oncol. 2012, 33(2), 138–141;
Published: 10 April 2012
Purpose of investigation: To assess the clinical relevance of serum growth-regulated oncogene α (GROα) levels in gynecological cancer, we investigated its concentration in distinguishing patients with cervical cancer, endometrial cancer, ovarian cancer, benign ovarian tumor and control. Methods: Preoperative serum GROα levels were measured in women with cervical cancer (n = 46), endometrial cancer (n = 39), ovarian cancer (n = 124), benign ovarian tumors (n = 52), and normal controls (n = 38) using an enzyme-linked immunosorbent assay. Results: Statistical analyses showed that the serum GROα concentration was significantly elevated in the cervical cancer, endometrial cancer and ovarian cancer patients compared with controls. Using GROα levels, the receiver operating characteristic (ROC) of cervical cancer (AUC ≈ 0.775), endometrial cancer (AUC ≈ 0.799), ovarian cancer (AUC ≈ 0.749) and benign ovarian tumors (AUC ≈ 0.568) vs controls were identified. Conclusion: Our findings suggest that serum GROα measurement as a molecular marker might contribute to detection and diagnosis of gynecological cancer.